Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - BetterLife Pharma (CSE: BETR), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.
Dates: | Tuesday April 25, 2023-Wednesday April 26, 2023 |
Time: | 8:30 AM-4:30 PM ET |
Location: | Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 |
Dr. Ahmad Doroudian & Dr. Hooshmand Sheshbaradaran will be speaking at 3:30 PM ET on April 26th. Interested parties can register to attend here.
Members of the BetterLife Pharma management will also be taking meetings throughout the day. Take advantage of the opportunity and reach out to the team.
To register and access, please follow this link.
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be potentially self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
About the Conference:
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Bloom Burton & Co.:
Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, as well as advisory on direct investing, company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).
For further information:
David Melles
Investor Relations Manager
778.887.1928
David.Melles@blifepharma.com
温哥华,不列颠哥伦比亚省-(Newsfile Corp.-2023年4月24日)-BetterLife制药公司(CSE:BETR),一家专注于精神障碍尖端治疗方法的开发和商业化的新兴生物技术公司,将参加2023年Bloom Burton&Co.Healthcare投资者大会,该会议将于4月25日和26日在多伦多大都会会议中心。
日期: | 2023年4月25日星期二-2023年4月26日星期三 |
时间: | 东部时间上午8:30-下午4:30 |
位置: | 多伦多大都会会议中心 北街255号楼前西街 安大略省多伦多 M5V 2W6 |
Ahmad Doroudian博士和Hooshmand Sheshbaradaran博士将于美国东部时间4月26日下午3:30发表讲话。有兴趣的人可以在这里注册参加。
BetterLife Pharma管理层的成员也将全天开会。利用这个机会,与团队接触。
要注册和访问,请点击此链接。
关于BetterLife Pharma
BetterLife制药公司是一家新兴的生物技术公司,主要致力于开发和商业化两种化合物BETR-001和BETR-002,用于治疗神经精神和神经疾病。Betr-001处于临床前研究和IND使能研究中,是一种开发中的非致幻和非受控LSD衍生物,其独特之处在于它不受监管,因此可以潜在地自我给药。BetterLife的BETR-001合成专利消除了管理障碍,其正在申请的成分和使用方法专利涵盖了治疗严重抑郁症、焦虑症和神经病理性疼痛以及其他神经精神和神经性疾病。Betr-002正在进行临床前和IND的研究,它是基于厚朴酚的,和厚朴酚是厚朴树皮的有效抗焦虑成分。BetterLife正在申请的使用方法和配方专利涵盖了治疗焦虑症相关疾病,包括对苯二氮卓的依赖。BetterLife还拥有一种治疗新冠肺炎等病毒感染的候选药物,并正在寻找进一步发展的战略替代药物。
关于会议:
Bloom Burton&Co.Healthcare投资者大会汇聚了对加拿大医疗行业最新发展感兴趣的美国、加拿大和国际投资者。与会者将有机会通过演讲和私人会议获得加拿大主要上市公司和私人公司的最新公司信息。
布鲁姆·伯顿公司简介:
Bloom Burton&Co.是一家致力于为投资者和公司加速医疗保健领域回报的公司。Bloom Burton拥有一支由医疗、科学、工业和资本市场专业人士组成的经验丰富的团队,他们的勤奋程度与我们的创意和创业方法相结合,帮助我们的客户实现正确的货币化活动。Bloom Burton及其附属公司提供融资、并购咨询、股票研究、商业战略和科学咨询,以及直接投资、公司创建和孵化服务的咨询。Bloom Burton证券公司是加拿大投资行业监管组织(IIROC)的成员,也是加拿大投资者保护基金(CIPF)的成员。
有关更多信息,请访问:
David·梅尔斯
投资者关系经理
778.887.1928
邮箱:David.Melle@blifepharma.com